healthandpharma2 天
FDA Approves Innovative ADC Datroway for Unresectable or Metastatic HR+, HER2- Breast Cancer
The FDA has approved Datroway® (datopotamab deruxtecan-dlnk) for adult patients with unresectable or metastatic HR-positive, ...
healthandpharma2 天
FDA Approves Sotorasib and Panitumumab Combination: Doubling Survival for KRAS G12C-Mutated ...
The FDA has approved a novel combination therapy using Lumakras® (sotorasib) and Vectibix® (panitumumab) for adults with KRAS ...
healthandpharma4 天
Regulatory Approval Boosts Pelareorep’s Innovative Oncolytic Virus Therapy for Pancreatic ...
Oncolytics Biotech received approval from Germany\u2019s Paul-Ehrlich-Institute to advance Cohort 5 of the GOBLET study, ...
healthandpharma5 天
FDA Approves 225Ac-SSO110 Radiopharmaceutical Trial for Small Cell Lung Cancer Patients
Ariceum Therapeutics announced that the FDA has cleared its investigational new drug application to commence a Phase I/II ...
healthandpharma5 天
The Internet of Medical Things needs a new security model to fulfil its potential
The Internet of Medical Things (IoMT) is set to radically change the quality of care and outcomes for millions of patients, ...
healthandpharma9 天
How AI Could Overcome Data Scarcity to Transform Medicine
Artificial Intelligence (AI) can play a crucial role in drug discovery, but the lack of sufficient data in this area remains ...
healthandpharma1 个月
AbbVie Acquires Nimble in $200 Million Deal to Strengthen Immunology Pipeline
AbbVie has announced plans to acquire Nimble Therapeutics in a $200 million deal. The acquisition brings Nimble’s pioneering oral peptide IL23R inhibitor, currently in preclinical development for ...
healthandpharma1 个月
FDA Approves BRAFTOVI Combo as First-Line Treatment for Colorectal Cancer
The US FDA has approved BRAFTOVI® (encorafenib) with cetuximab and mFOLFOX6 as a first-line therapy for BRAF V600E-mutant metastatic colorectal cancer. The Phase 3 BREAKWATER trial showed ...